Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting

Current TAP Partner

Carisma

PHILADELPHIA, April 8, 2022 /PRNewswire/ -- Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for presentation at The American Association for Cancer Research (AACR) Annual Meeting taking place in New Orleans, LA, Friday, April 8 – Wednesday, April 13. The accepted data reinforce the potential of Carisma's differentiated and proprietary cell therapy platform focused on engineered macrophages as a novel treatment pathway for hard-to-treat cancers and other serious illnesses and provides information on the feasibility of a shortened manufacturing process for chimeric antigen receptor (CAR) monocytes.

The following poster presentations will be published on the AACR Annual Meeting website and available for registered attendees during the dates/times indicated below:

  • Sunday, April 10 at 1:30 pm ET:
    • Pre-clinical development of CAR Monocytes (CAR-Mono) for solid tumor immunotherapy
  • Monday, April 11 at 1:30 pm ET:
    • Chimeric antigen receptor macrophages (CAR-M) sensitize solid tumors to anti-PD1 immunotherapy
  • Tuesday, April 12 at 9:00 am ET:
    • A phase 1, first in human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophages (CAR-M) in HER2-overexpressing solid tumors (ST)